Quest for correlates of protection against tuberculosis

Clinical and Vaccine Immunology

Volumn 22, Issue 3, 2015, Pages 258-266

  Bhatt, Kamlesh ^a   Verma, Sheetal ^a   Ellner, Jerrold J ^b   Salgame, Padmini ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; ISONIAZID; TUMOR NECROSIS FACTOR; BIOLOGICAL MARKER; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN SPECIFICITY; CD4+ T LYMPHOCYTE; DRUG EFFICACY; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; MEMORY T LYMPHOCYTE; MYCOBACTERIUM TUBERCULOSIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TH17 CELL; TUBERCULOSIS; TUBERCULOSIS CONTROL; VACCINATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MYCOBACTERIUM BOVIS;

BCG VACCINE; BIOMARKERS; CD4-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; INTERLEUKIN-2; KILLER CELLS, NATURAL; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; TH17 CELLS; TUBERCULOSIS; TUBERCULOSIS VACCINES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84923926897     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00721-14     Document Type: Review

References (105)

1. World Health Organization. 2014. Global tuberculosis report 2014.World Health Organization, Geneva, Switzerland. http://www.who.int/tb/publications/global-report/en/.
2. Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, Fineberg HV. 1995. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: metaanalyses of the published literature. Pediatrics 96:29-35.
3. Ottenhoff TH, Kaufmann SH. 2012. Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog 8:e1002607. http://dx.doi.org/10.1371/journal.ppat.1002607.
4. Kaufmann SH. 2012. Tuberculosis vaccine development: strength lies in tenacity. Trends Immunol 33:373-379. http://dx.doi.org/10.1016/j.it.2012.03.004.
5. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, Mahomed H, McShane H, Team MATS. 2013. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381: 1021-1028. http://dx.doi.org/10.1016/S0140-6736(13)60177-4.
6. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, Fletcher HA, Hill AVS. 2004. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10:1240-1244. http://dx.doi.org/10.1038/nm1128.
7. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. 1993. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178:2249-2254. http://dx.doi.org/10.1084/jem.178.6.2249.
8. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. 1993. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 178:2243-2247. http://dx.doi.org/10.1084/jem.178.6.2243.
9. Seneviratne SL, Doffinger R, Macfarlane J, Ceron-Gutierrez L, Amel Kashipaz MR, Robbins A, Patel T, Powell PT, Kumararatne DS, Powell RJ. 2007. Disseminated Mycobacterium tuberculosis infection due to interferon γ deficiency. Response to replacement therapy. Thorax 62:97-99. http://dx.doi.org/10.1136/thx.2005.051649.
10. Jouanguy E, Altare F, Lamhamedi S, Revy P, Emile J-F, Newport M, Levin M, Blanche S, Seboun E, Fischer A, Casanova J-L. 1996. Inter-feron- γ-receptor deficiency in an infant with fatal Bacille Calmette- Guérin infection. N Engl J Med 335:1956-1962. http://dx.doi.org/10.1056/NEJM199612263352604.
11. Hirsch CS, Toossi Z, Othieno C, Johnson JL, Schwander SK, Robertson S, Wallis RS, Edmonds K, Okwera A, Mugerwa R, Peters P, Ellner JJ. 1999. Depressed T-cell interferon-gamma responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy. J Infect Dis 180:2069-2073. http://dx.doi.org/10.1086/315114.
12. Elias D, Akuffo H, Britton S. 2005. PPD induced in vitro interferon gamma production is not a reliable correlate of protection against Mycobacterium tuberculosis. Trans R Soc Trop Med Hyg 99:363-368. http://dx.doi.org/10.1016/j.trstmh.2004.08.006.
13. Mittrücker H-W, Steinhoff U, Köhler A, Krause M, Lazar D, Mex P, Miekley D, Kaufmann SHE. 2007. Poor correlation between BCG vac-cination- induced T cell responses and protection against tuberculosis. Proc Natl Acad Sci U S A 104:12434-12439. http://dx.doi.org/10.1073/pnas.0703510104.
14. Caccamo N, Guggino G, Joosten SA, Gelsomino G, Di Carlo P, Titone L, Galati D, Bocchino M, Matarese A, Salerno A, Sanduzzi A, Franken WPJ, Ottenhoff THM, Dieli F. 2010. Multifunctional CD4+ T cells correlate with active Mycobacterium tuberculosis infection. Eur J Immunol 40:2211-2220. http://dx.doi.org/10.1002/eji.201040455.
15. Mattila JT, Diedrich CR, Lin PL, Phuah J, Flynn JL. 2011. Simian immunodeficiency virus-induced changes in T cell cytokine responses in cynomolgus macaques with latent Mycobacterium tuberculosis infection are associated with timing of reactivation. J Immunol 186:3527-3537. http://dx.doi.org/10.4049/jimmunol.1003773.
16. Winkler S, Necek M, Winkler H, Adegnika AA, Perkmann T, Ramharter M, Kremsner PG. 2005. Increased specific T cell cytokine responses in patients with active pulmonary tuberculosis from Central Africa. Microbes Infect 7:1161-1169. http://dx.doi.org/10.1016/j.micinf.2005.03.020.
17. Duvall MG, Precopio ML, Ambrozak DA, Jaye A, McMichael AJ, Whittle HC, Roederer M, Rowland-Jones SL, Koup RA. 2008. Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol 38:350-363. http://dx.doi.org/10.1002/eji.200737768.
18. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, Hoff ST, Andersen P, Reed SG, Morris SL, Roederer M, Seder RA. 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13:843-850. http://dx.doi.org/10.1038/nm1592.
19. Lindenstrøm T, Agger EM, Korsholm KS, Darrah PA, Aagaard C, Seder RA, Rosenkrands I, Andersen P. 2009. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol 182:8047-8055. http://dx.doi.org/10.4049/jimmunol.0801592.
20. Derrick SC, Yabe IM, Yang A, Morris SL. 2011. Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells. Vaccine 29:2902-2909. http://dx.doi.org/10.1016/j.vaccine.2011.02.010.
21. Kagina BMN, Abel B, Scriba TJ, Hughes EJ, Keyser A, Soares A, Gamieldien H, Sidibana M, Hatherill M, Gelderbloem S, Mahomed H, Hawkridge A, Hussey G, Kaplan G, Hanekom WA. 2010. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. Am J Respir Crit Care Med 182:1073-1079. http://dx.doi.org/10.1164/rccm.201003-0334OC.
22. Hawkridge T, Scriba TJ, Gelderbloem S, Smit E, Tameris M, Moyo S, Lang T, Veldsman A, Hatherill M, Merwe L, Fletcher HA, Mahomed H, Hill AV, Hanekom WA, Hussey GD, McShane H. 2008. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis 198:544-552. http://dx.doi.org/10.1086/590185.
23. Gallegos AM, van Heijst JW, Samstein M, Su X, Pamer EG, Glickman MS. 2011. A gamma interferon independent mechanism of CD4 T cell mediated control of M. tuberculosis infection in vivo. PLoS Pathog 7:e1002052. http://dx.doi.org/10.1371/journal.ppat.1002052.
24. Wozniak TM, Saunders BM, Ryan AA, Britton WJ. 2010. Mycobacterium bovis BCG-specific Th17 cells confer partial protection against Mycobacterium tuberculosis infection in the absence of gamma interferon. Infect Immun 78:4187-4194. http://dx.doi.org/10.1128/IAI.01392-09.
25. Gopal R, Rangel-Moreno J, Slight S, Lin Y, Nawar HF, Fallert Junecko BA, Reinhart TA, Kolls J, Randall TD, Connell TD, Khader SA. 2013. Interleukin-17-dependent CXCL13 mediates mucosal vaccine-induced immunity against tuberculosis. Mucosal Immunol 6:972-984. http://dx.doi.org/10.1038/mi.2012.135.
26. Cowley SC, Elkins KL. 2003. CD4+ T cells mediate IFN-gamma-independent control of Mycobacterium tuberculosis infection both in vitro and in vivo. J Immunol 171:4689-4699. http://dx.doi.org/10.4049/jimmunol.171.9.4689.
27. Hinchey J, Lee S, Jeon BY, Basaraba RJ, Venkataswamy MM, Chen B, Chan J, Braunstein M, Orme IM, Derrick SC, Morris SL, Jacobs WR, Jr, Porcelli SA. 2007. Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J Clin Invest 117: 2279-2288. http://dx.doi.org/10.1172/JCI31947.
28. Chen CY, Huang D, Wang RC, Shen L, Zeng G, Yao S, Shen Y, Halliday L, Fortman J, McAllister M, Estep J, Hunt R, Vasconcelos D, Du G, Porcelli SA, Larsen MH, Jacobs WR, Jr, Haynes BF, Letvin NL, Chen ZW. 2009. A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS Pathog 5:e1000392. http://dx.doi.org/10.1371/journal.ppat.1000392.
29. Bruns H, Meinken C, Schauenberg P, Harter G, Kern P, Modlin RL, Antoni C, Stenger S. 2009. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 119:1167-1177. http://dx.doi.org/10.1172/JCI38482.
30. Ehlers S. 2005. Why does tumor necrosis factor targeted therapy reactivate tuberculosis? J Rheumatol Suppl 74:35-39.
31. Khader SA, Guglani L, Rangel-Moreno J, Gopal R, Junecko BA, Fountain JJ, Martino C, Pearl JE, Tighe M, Lin YY, Slight S, Kolls JK, Reinhart TA, Randall TD, Cooper AM. 2011. IL-23 is required for long-term control of Mycobacterium tuberculosis and B cell follicle formation in the infected lung. J Immunol 187:5402-5407. http://dx.doi.org/10.4049/jimmunol.1101377.
32. Khader SA, Pearl JE, Sakamoto K, Gilmartin L, Bell GK, Jelley-Gibbs DM, Ghilardi N, deSauvage F, Cooper AM. 2005. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN- {gamma} responses if IL-12p70 is available. J Immunol 175:788-795. http://dx.doi.org/10.4049/jimmunol.175.2.788.
33. Freches D, Korf H, Denis O, Havaux X, Huygen K, Romano M. 2013. Mice genetically inactivated in interleukin-17A receptor are defective in long-term control of Mycobacterium tuberculosis infection. Immunology 140:220-231. http://dx.doi.org/10.1111/imm.12130.
34. Gopal R, Monin L, Slight S, Uche U, Blanchard E, Fallert Junecko BA, Ramos-Payan R, Stallings CL, Reinhart TA, Kolls JK, Kaushal D, Nagarajan U, Rangel-Moreno J, Khader SA. 2014. Unexpected role for IL-17 in protective immunity against hypervirulent Mycobacterium tuberculosis HN878 infection. PLoS Pathog 10:e1004099. http://dx.doi.org/10.1371/journal.ppat.1004099.
35. Gopal R, Lin Y, Obermajer N, Slight S, Nuthalapati N, Ahmed M, Kalinski P, Khader SA. 2012. IL-23-dependent IL-17 drives Th1-cell responses following Mycobacterium bovis BCG vaccination. Eur J Immunol 42:364-373. http://dx.doi.org/10.1002/eji.201141569.
36. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, Shen F, Eaton SM, Gaffen SL, Swain SL, Locksley RM, Haynes L, Randall TD, Cooper AM. 2007. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8:369-377. http://dx.doi.org/10.1038/ni1449.
37. Chen K, McAleer JP, Lin Y, Paterson DL, Zheng M, Alcorn JF, Weaver CT, Kolls JK. 2011. Th17 cells mediate clade-specific, serotype-independent mucosal immunity. Immunity 35:997-1009. http://dx.doi.org/10.1016/j.immuni.2011.10.018.
38. Wuthrich M, Gern B, Hung CY, Ersland K, Rocco N, Pick-Jacobs J, Galles K, Filutowicz H, Warner T, Evans M, Cole G, Klein B. 2011. Vaccine-induced protection against 3 systemic mycoses endemic to North America requires Th17 cells in mice. J Clin Invest 121:554-568. http://dx.doi.org/10.1172/JCI43984.
39. Carlson MJ, West ML, Coghill JM, Panoskaltsis-Mortari A, Blazar BR, Serody JS. 2009. In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood 113:1365-1374. http://dx.doi.org/10.1182/blood-2008-06-162420.
40. Muranski P, Borman ZA, Kerkar SP, Klebanoff CA, Ji Y, Sanchez-Perez L, Sukumar M, Reger RN, Yu Z, Kern SJ, Roychoudhuri R, Ferreyra GA, Shen W, Durum SK, Feigenbaum L, Palmer DC, Antony PA, Chan CC, Laurence A, Danner RL, Gattinoni L, Restifo NP. 2011. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity 35:972-985. http://dx.doi.org/10.1016/j.immuni.2011.09.019.
41. Kryczek I, Zhao E, Liu Y, Wang Y, Vatan L, Szeliga W, Moyer J, Klimczak A, Lange A, Zou W. 2011. Human TH17 cells are long-lived effector memory cells. Sci Transl Med 3:104ra100. http://dx.doi.org/10.1126/scitranslmed.3002949.
42. Zhang Y, Joe G, Hexner E, Zhu J, Emerson SG. 2005. Host-reactive CD8+ memory stem cells in graft-versus-host disease. Nat Med 11: 1299-1305. http://dx.doi.org/10.1038/nm1326.
43. Zhao DM, Yu S, Zhou X, Haring JS, Held W, Badovinac VP, Harty JT, Xue HH. 2010. Constitutive activation of Wnt signaling favors generation of memory CD8 T cells. J Immunol 184:1191-1199. http://dx.doi.org/10.4049/jimmunol.0901199.
44. Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, Wrzesinski C, Boni A, Cassard L, Garvin LM, Paulos CM, Muranski P, Restifo NP. 2009. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. NatMed 15:808-813. http://dx.doi.org/10.1038/nm.1982.
45. Staal FJ, Luis TC, Tiemessen MM. 2008. WNT signalling in the immune system: WNT is spreading its wings. Nat Rev Immunol 8:581-593. http://dx.doi.org/10.1038/nri2360.
46. Fleming HE, Janzen V, Lo Celso C, Guo J, Leahy KM, Kronenberg HM, Scadden DT. 2008. Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell 2:274-283. http://dx.doi.org/10.1016/j.stem.2008.01.003.
47. Andersen P, Smedegaard B. 2000. CD4(+) T-cell subsets that mediate immunological memory to Mycobacterium tuberculosis infection in mice. Infect Immun 68:621-629. http://dx.doi.org/10.1128/IAI.68.2.621 -629.2000.
48. Kipnis A, Irwin S, Izzo AA, Basaraba RJ, Orme IM. 2005. Memory T lymphocytes generated by Mycobacterium bovis BCG vaccination reside within a CD4 CD44lo CD62 ligand(hi) population. Infect Immun 73: 7759-7764. http://dx.doi.org/10.1128/IAI.73.11.7759-7764.2005.
49. Paust S, von Andrian UH. 2011. Natural killer cell memory. Nat Immunol 12:500-508. http://dx.doi.org/10.1038/ni.2032.
50. Colucci F, Caligiuri MA, Di Santo JP. 2003. What does it take to make a natural killer? Nat Rev Immunol 3:413-425. http://dx.doi.org/10.1038/nri1088.
51. Junqueira-Kipnis AP, Kipnis A, Jamieson A, Juarrero MG, Diefenbach A, Raulet DH, Turner J, Orme IM. 2003. NK cells respond to pulmonary infection with Mycobacterium tuberculosis, but play a minimal role in protection. J Immunol 171:6039-6045. http://dx.doi.org/10.4049/jimmunol.171.11.6039.
52. Feng CG, Kaviratne M, Rothfuchs AG, Cheever A, Hieny S, Young HA, Wynn TA, Sher A. 2006. NK cell-derived IFN-gamma differentially regulates innate resistance and neutrophil response in T cell-deficient hosts infected with Mycobacterium tuberculosis. J Immunol 177:7086-7093. http://dx.doi.org/10.4049/jimmunol.177.10.7086.
53. Vankayalapati R, Wizel B, Weis SE, Safi H, Lakey DL, Mandelboim O, Samten B, Porgador A, Barnes PF. 2002. The NKp46 receptor contributes to NK cell lysis of mononuclear phagocytes infected with an intracellular bacterium. J Immunol 168:3451-3457. http://dx.doi.org/10.4049/jimmunol.168.7.3451.
54. Vankayalapati R, Garg A, Porgador A, Griffith DE, Klucar P, Safi H, Girard WM, Cosman D, Spies T, Barnes PF. 2005. Role of NK cell-activating receptors and their ligands in the lysis of mononuclear phagocytes infected with an intracellular bacterium. J Immunol 175:4611-4617. http://dx.doi.org/10.4049/jimmunol.175.7.4611.
55. Dhiman R, Indramohan M, Barnes PF, Nayak RC, Paidipally P, Rao LV, Vankayalapati R. 2009. IL-22 produced by human NK cells inhibits growth of Mycobacterium tuberculosis by enhancing phagolysosomal fusion. J Immunol 183:6639-6645. http://dx.doi.org/10.4049/jimmunol.0902587.
56. Gasteiger G, Hemmers S, Bos PD, Sun JC, Rudensky AY. 2013. IL-2-dependent adaptive control of NK cell homeostasis. J Exp Med 210: 1179-1187. http://dx.doi.org/10.1084/jem.20122571.
57. Firth MA, Madera S, Beaulieu AM, Gasteiger G, Castillo EF, Schluns KS, Kubo M, Rothman PB, Vivier E, Sun JC. 2013. Nfil3-independent lineage maintenance and antiviral response of natural killer cells. J Exp Med 210:2981-2990. http://dx.doi.org/10.1084/jem.20130417.
58. Sun JC, Beilke JN, Lanier LL. 2009. Adaptive immune features of naturalkiller cells. Nature 457:557-561.http://dx.doi.org/10.1038/nature 07665.
59. Dhiman R, Periasamy S, Barnes PF, Jaiswal AG, Paidipally P, Barnes AB, Tvinnereim A, Vankayalapati R. 2012. NK1.1+ cells and IL-22 regulate vaccine-induced protective immunity against challenge with Mycobacterium tuberculosis. J Immunol 189:897-905. http://dx.doi.org/10.4049/jimmunol.1102833.
60. Boom WH. 1999. Gammadelta T cells and Mycobacterium tuberculosis. Microbes Infect 1:187-195. http://dx.doi.org/10.1016/S1286-4579(99)80033-1.
61. Poccia F, Malkovsky M, Pollak A, Colizzi V, Sireci G, Salerno A, Dieli F. 1999. In vivo gammadelta T cell priming to mycobacterial antigens by primary Mycobacterium tuberculosis infection and exposure to nonpeptidic ligands. Mol Med 5:471-476.
62. Lockhart E, Green AM, Flynn JL. 2006. IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J Immunol 177:4662-4669. http://dx.doi.org/10.4049/jimmunol.177.7.4662.
63. Dieli F, Ivanyi J, Marsh P, Williams A, Naylor I, Sireci G, Caccamo N, Di Sano C, Salerno A. 2003. Characterization of lung gamma delta T cells following intranasal infection with Mycobacterium bovis bacillus Calmette-Guerin. J Immunol 170:463-469. http://dx.doi.org/10.4049/jimmunol.170.1.463.
64. Janis EM, Kaufmann SH, Schwartz RH, Pardoll DM. 1989. Activation of gamma delta T cells in the primary immune response to Mycobacterium tuberculosis. Science 244:713-716. http://dx.doi.org/10.1126/science.2524098.
65. Okamoto Yoshida Y, Umemura M, Yahagi A, O'Brien RL, Ikuta K, Kishihara K, Hara H, Nakae S, Iwakura Y, Matsuzaki G. 2010. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol 184:4414-4422. http://dx.doi.org/10.4049/jimmunol.0903332.
66. Nabeshima S, Hiromatsu K, Matsuzaki G, Mukasa A, Takada H, Yoshida S, Nomoto K. 1995. Infection of Mycobacterium bovis bacillus Calmette-Guerin in antibody-mediated gamma delta T-cell-depleted mice. Immunology 84:317-321.
67. Shen Y, Zhou D, Qiu L, Lai X, Simon M, Shen L, Kou Z, Wang Q, Jiang L, Estep J, Hunt R, Clagett M, Sehgal PK, Li Y, Zeng X, Morita CT, Brenner MB, Letvin NL, Chen ZW. 2002. Adaptive immune response of Vgamma2Vdelta2+ T cells during mycobacterial infections. Science 295:2255-2258. http://dx.doi.org/10.1126/science.1068819.
68. Dieli F, Troye-Blomberg M, Ivanyi J, Fournie JJ, Bonneville M, Peyrat MA, Sireci G, Salerno A. 2000. Vgamma9/Vdelta2 T lymphocytes reduce the viability of intracellular Mycobacterium tuberculosis. Eur J Immunol 30:1512-1519. http://dx.doi.org/10.1002/(SICI)1521-4141 (200005)30:5〈1512::AID-IMMU1512〉3.0.CO;2-3.
69. Spencer CT, Abate G, Sakala IG, Xia M, Truscott SM, Eickhoff CS, Linn R, Blazevic A, Metkar SS, Peng G, Froelich CJ, Hoft DF. 2013. Granzyme A produced by gamma(9)delta(2) T cells induces human macrophages to inhibit growth of an intracellular pathogen. PLoS Pathog 9:e1003119. http://dx.doi.org/10.1371/journal.ppat.1003119.
70. Dieli F, Troye-Blomberg M, Ivanyi J, Fournie JJ, Krensky AM, Bonneville M, Peyrat MA, Caccamo N, Sireci G, Salerno A. 2001. Granu-lysin- dependent killing of intracellular and extracellular Mycobacterium tuberculosis by Vgamma9/Vdelta2 T lymphocytes. J Infect Dis 184: 1082-1085. http://dx.doi.org/10.1086/323600.
71. Lee J, Choi K, Olin MR, Cho SN, Molitor TW. 2004. Gammadelta T cells in immunity induced by Mycobacterium bovis bacillus Calmette- Guerin vaccination. Infect Immun 72:1504-1511. http://dx.doi.org/10.1128/IAI.72.3.1504-1511.2004.
72. Hoft DF, Brown RM, Roodman ST. 1998. Bacille Calmette-Guerin vaccination enhances human gamma delta T cell responsiveness to mycobacteria suggestive of a memory-like phenotype. J Immunol 161: 1045-1054.
73. Cowley SC, Hamilton E, Frelinger JA, Su J, Forman J, Elkins KL. 2005. CD4-CD8- T cells control intracellular bacterial infections both in vitro and in vivo. J Exp Med 202:309-319. http://dx.doi.org/10.1084/jem.20050569.
74. Derrick SC, Repique C, Snoy P, Yang AL, Morris S. 2004. Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosis. Infect Immun 72:1685-1692. http://dx.doi.org/10.1128/IAI.72.3.1685-1692.2004.
75. Wang J, Santosuosso M, Ngai P, Zganiacz A, Xing Z. 2004. Activation of CD8 T cells by mycobacterial vaccination protects against pulmonary tuberculosis in the absence of CD4 T cells. J Immunol 173:4590-4597. http://dx.doi.org/10.4049/jimmunol.173.7.4590.
76. Sambandamurthy VK, Derrick SC, Hsu T, Chen B, Larsen MH, Jalapathy KV, Chen M, Kim J, Porcelli SA, Chan J, Morris SL, Jacobs WR, Jr. 2006. Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. Vaccine 24: 6309-6320. http://dx.doi.org/10.1016/j.vaccine.2006.05.097.
77. Derrick SC, Evering TH, Sambandamurthy VK, Jalapathy KV, Hsu T, Chen B, Chen M, Russell RG, Junqueira-Kipnis AP, Orme IM, Porcelli SA, Jacobs WR, Jr, Morris SL. 2007. Characterization of the protective T-cell response generated in CD4-deficient mice by a live attenuated Mycobacterium tuberculosis vaccine. Immunology 120:192-206. http://dx.doi.org/10.1111/j.1365-2567.2006.02491.x.
78. Zufferey C, Germano S, Dutta B, Ritz N, Curtis N. 2013. The contribution of non-conventional T cells and NK cells in the mycobacterialspecific IFNgamma response in Bacille Calmette-Guerin (BCG)- immunized infants. PLoS One 8:e77334. http://dx.doi.org/10.1371/journal.pone.0077334.
79. Sun JC, Ugolini S, Vivier E. 2014. Immunological memory within the innate immune system. EMBO J 33:1295-1303. http://dx.doi.org/10.1002/embj.201387651.
80. Kurtz J, Franz K. 2003. Innate defence: evidence for memory in invertebrate immunity. Nature 425:37-38. http://dx.doi.org/10.1038/425037a.
81. Dong Y, Cirimotich CM, Pike A, Chandra R, Dimopoulos G. 2012. Anopheles NF-kappaB-regulated splicing factors direct pathogenspecific repertoires of the hypervariable pattern recognition receptor AgDscam. Cell Host Microbe 12:521-530. http://dx.doi.org/10.1016/j.chom.2012.09.004.
82. Pham LN, Dionne MS, Shirasu-Hiza M, Schneider DS. 2007. A specific primed immune response in Drosophila is dependent on phagocytes. PLoS Pathog 3:e26. http://dx.doi.org/10.1371/journal.ppat.0030026.
83. Leclerc V, Reichhart JM. 2004. The immune response of Drosophila melanogaster. Immunol Rev 198:59-71. http://dx.doi.org/10.1111/j.0105-2896.2004.0130.x.
84. Netea MG. 2013. Training innate immunity: the changing concept of immunological memory in innate host defence. Eur J Clin Invest 43:881-884. http://dx.doi.org/10.1111/eci.12132.
85. Akira S. 2006. TLR signaling. Curr Top Microbiol Immunol 311:1-16.
86. Foster SL, Hargreaves DC, Medzhitov R. 2007. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 447: 972-978. http://dx.doi.org/10.1038/nature05836.
87. Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Ifrim DC, Saeed S, Jacobs C, van Loenhout J, de Jong D, Stunnenberg HG, Xavier RJ, van der Meer JW, van Crevel R, Netea MG. 2012. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A 109: 17537-17542. http://dx.doi.org/10.1073/pnas.1202870109.
88. Jeyanathan M, Damjanovic D, Shaler CR, Lai R, Wortzman M, Yin C, Zganiacz A, Lichty BD, Xing Z. 2013. Differentially imprinted innate immunity by mucosal boost vaccination determines antituberculosis immune protective outcomes, independent of T-cell immunity. Mucosal Immunol 6:612-625. http://dx.doi.org/10.1038/mi.2012.103.
89. Strutt TM, McKinstry KK, Dibble JP, Winchell C, Kuang Y, Curtis JD, Huston G, Dutton RW, Swain SL. 2010. Memory CD4+ T cells induce innate responses independently of pathogen. Nat Med 16:558-564. http: //dx.doi.org/10.1038/nm.2142.
90. Strutt TM, McKinstry KK, Kuang Y, Bradley LM, Swain SL. 2012. Memory CD4+ T-cell-mediated protection depends on secondary effectors that are distinct from and superior to primary effectors. Proc Natl Acad Sci U S A 109:E2551-E2560. http://dx.doi.org/10.1073/pnas.12058 94109.
91. Soudja SM, Chandrabos C, Yakob E, Veenstra M, Palliser D, Lauvau G. 2014. Memory-T-cell-derived interferon-gamma instructs potent innate cell activation for protective immunity. Immunity 40:974-988. http://dx.doi.org/10.1016/j.immuni.2014.05.005.
92. Tanca A, Deligios M, Addis MF, Uzzau S. 2013. High throughput genomic and proteomic technologies in the fight against infectious diseases. J Infect Dev Ctries 7:182-190. http://dx.doi.org/10.3855/jidc.3027.
93. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, Pirani A, Gernert K, Deng J, Marzolf B, Kennedy K, Wu H, Bennouna S, Oluoch H, Miller J, Vencio RZ, Mulligan M, Aderem A, Ahmed R, Pulendran B. 2009. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 10:116-125. http: //dx.doi.org/10.1038/ni.1688.
94. Nakaya HI, Wrammert J, Lee EK, Racioppi L, Marie-Kunze S, Haining WN, Means AR, Kasturi SP, Khan N, Li G-M, McCausland M, Kanchan V, Kokko KE, Li S, Elbein R, Mehta AK, Aderem A, Subbarao K, Ahmed R, Pulendran B. 2011. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 12:786-795. http://dx.doi.org/10.1038/ni.2067.
95. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, Wilkinson KA, Banchereau R, Skinner J, Wilkinson RJ, Quinn C, Blankenship D, Dhawan R, Cush JJ, Mejias A, Ramilo O, Kon OM, Pascual V, Banchereau J, Chaussabel D, O'Garra A. 2010. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466:973-977. http://dx.doi.org/10.1038/nature09247.
96. Mistry R, Cliff JM, Clayton CL, Beyers N, Mohamed YS, Wilson PA, Dockrell HM, Wallace DM, van Helden PD, Duncan K, Lukey PT. 2007. Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis. J Infect Dis 195:357-365. http://dx.doi.org/10.1086/510397.
97. Maertzdorf J, Ota M, Repsilber D, Mollenkopf HJ, Weiner J, Hill PC, Kaufmann SHE. 2011. Functional correlations of pathogenesis-driven gene expression signatures in tuberculosis. PLoS One 6:e26938. http://dx.doi.org/10.1371/journal.pone.0026938.
98. Ottenhoff THM, Dass RH, Yang N, Zhang MM, Wong HEE, Sahiratmadja E, Khor CC, Alisjahbana B, van Crevel R, Marzuki S, Seielstad M, van de Vosse E, Hibberd ML. 2012. Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis. PLoS One 7:e45839. http://dx.doi.org/10.1371/journal.pone.0045839.
99. Lesho E, Forestiero FJ, Hirata MH, Hirata RD, Cecon L, Melo FF, Paik SH, Murata Y, Ferguson EW, Wang Z, Ooi GT. 2011. Transcriptional responses of host peripheral blood cells to tuberculosis infection. Tuberculosis 91:390-399. http://dx.doi.org/10.1016/j.tube.2011.07.002.
100. Bloom CI, Graham CM, Berry MPR, Rozakeas F, Redford PS, Wang Y, Xu Z, Wilkinson KA, Wilkinson RJ, Kendrick Y, Devouassoux G, Ferry T, Miyara M, Bouvry D, Dominique V, Gorochov G, Blankenship D, Saadatian M, Vanhems P, Beynon H, Vancheeswaran R, Wickremasinghe M, Chaussabel D, Banchereau J, Pascual V, Ho L-P, Lipman M, O'Garra A. 2013. Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS One 8:e70630. http://dx.doi.org/10.1371/journal.pone.0070630.
101. Jacobsen M, Repsilber D, Gutschmidt A, Neher A, Feldmann K, Mollenkopf H, Ziegler A, Kaufmann SE. 2007. Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. J Mol Med 85:613-621. http://dx.doi.org/10.1007/s00109-007-0157-6.
102. Johnson DF, Malone LL, Zalwango S, Mukisa Oketcho J, Chervenak KA, Thiel B, Mayanja-Kizza H, Stein CM, Boom WH, Lancioni CL, Tuberculosis Research Unit. 2014. Tuberculin skin test reversion following isoniazid preventive therapy reflects diversity of immune response to primary Mycobacterium tuberculosis infection. PLoS One 9:e96613. http://dx.doi.org/10.1371/journal.pone.0096613.
103. Chattopadhyay PK, Gierahn TM, Roederer M, Love JC. 2014. Singlecell technologies for monitoring immune systems. Nat Immunol 15: 128-135. http://dx.doi.org/10.1038/ni.2796.
104. Aderem A, Adkins JN, Ansong C, Galagan J, Kaiser S, Korth MJ, Law GL, McDermott JG, Proll SC, Rosenberger C, Schoolnik G, Katze MG. 2011. A systems biology approach to infectious disease research: innovating the pathogen-host research paradigm. mBio 2(1):e00325-10. http: //dx.doi.org/10.1128/mBio.00325-10.
105. Fine PEM. 1995. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346:1339-1345. http://dx.doi.org/10.1016/S0140-6736(95)92348-9.